Sign in
CompletedNo phase

Short-Term Cardiovascular Effects of E-Cigarettes: Influence of E-Liquid pH

Key facts

Who runs it
University of California, San Francisco
Where
San Francisco, United StatesSee the 2 sites
Trial code
Status
Completed
People taking part
14 people enrolled
Started
4 Jan 2021
Ended
31 Jul 2024
Type of study
Interventional, 3 groups
Treatments tested
  • Electronic Cigarette
Record updated
15 July 2025

Who can take part

Age
21 years to 70 years
Sex
Women and men
Healthy volunteers
Can take part

The registry criteria, word for word

Show all 53 criteriaShow less

Who can take part

  • Heart rate < 105 beats per minute (BPM)*
  • Systolic Blood pressure <160 and > 90*
  • Diastolic Blood Pressure <100 and > 50*
  • Body Mass Index (BMI) < 38.0 (at investigator's discretion for higher BMI if no other concurrent health issues); *considered out of range if both machine and manual readings are above/below these thresholds
  • Use e-cigarettes on at least 15 days in the past 30 for at least 3 months
  • Smoke 10 or fewer cigarettes/tobacco products per day in the last 30 days
  • Willing to use mod e-cigarette
  • Willing to abstain from tobacco product use for night before study
  • Age: > 21 years old and < 70 years old
  • Using e-liquid > 0mg/ml nicotine
  • Saliva cotinine of ≥ 30 ng/ml or NicAlert=6 (in cases where lab turn around time will delay study procedure)

Who cannot take part

  • High Blood Pressure (taking sympatholytic medications such as alpha and beta blockers)
  • Drug/Alcohol Dependence
  • Alcohol or illicit drug dependence within the past 12 months with the exception of those who have recently completed an alcohol/drug treatment program
  • Positive toxicology test at the screening visit (THC \& prescribed medications okay)
  • Opioid replacement therapy (including methadone, buprenorphine, or other)
  • Medications
  • Use of medications that are inducers of nicotine metabolizing enzyme CYP2A4 (Example: rifampicin, carbamazepine, phenobarbital, and other anticonvulsant drugs)
  • Concurrent use of nicotine-containing medications
  • Concurrent participation in another clinical trial
  • Seizures
  • Cancer
  • Hepatitis B or C or Liver Disease
  • Heart disease
  • Kidney disease or urinary retention
  • Diabetes
  • History of stroke
  • An ulcer in the past year
  • Thyroid disease (okay if controlled with medication)
  • Active use of an inhaler for asthma or Chronic Obstructive Pulmonary Disease (COPD)
  • Psychiatric conditions
  • Current or past schizophrenia, and/or current or past bipolar disorder
  • Major personality disorder
  • Participants with current or past minor or moderate depression and/or anxiety disorders will be reviewed by the study physician and considered for inclusion
  • History of psychiatric hospitalizations are not exclusionary, but study participation will be determined as per study physician's approval
  • Psychiatric medications
  • Current regular use of any psychiatric medications with the exception of Selective Serotonin Reuptake Inhibitor (SSRI) and serotonin-norepinephrine reuptake Inhibitor (SNRIs) and current evaluation by the study physician that the participant is otherwise healthy, stable, and able to participate
  • Any stimulant medications (example: Adderall) generally given for Attention deficit hyperactivity disorder (ADHD) treatment
  • Use of sympatholytic medications that affect cardiovascular conditions including hypertension, (Example: beta and alpha-blockers)
  • Other/Misc. Chronic Health Conditions
  • Other "life threatening illnesses" as per study physician's discretion
  • Oral Thrush
  • Glaucoma
  • Major depression, current or within the past year
  • Recent onset or change in cough, fever and/or abdominal symptoms (vomiting or pain) in the past two weeks. (If yes, participant can re-screen when symptoms resolve)
  • Positive urine cannabis is not exclusionary but participant must report use of cannabis and agree to abstain from cannabis use for the duration of the study
  • Fainting (within the last 30 days)
  • Pregnancy
  • Pregnancy (self-reported and urine pregnancy test)
  • Breastfeeding (determined by self-report)
  • Inability to communicate in English
  • Planning to quit vaping within the next 60 days
  • Uncomfortable with getting blood drawn

Where in United States

  • University of California San FranciscoSan Francisco, United States
  • Zuckerberg San Francisco General HospitalSan Francisco, United States

About the trial

What the trial wants to find out

This study will examine the short-term cardiovascular (CV) effects of e-liquid pH in a randomized, crossover clinical and behavioral pharmacology study of experienced adult e-cigarette users (N=21). The specific aim is to determine the impact of e-cigarette pH levels on nicotine pharmacology, systemic exposure to toxic volatile organic compounds (VOCs), and short-term cardiovascular effects.

The 3 groups in the trial

  • E-liquid pH 5, 7, or 9Other group

    Using an electronic cigarette, the participant will complete a standardized vaping session using 1 of 3 assigned e-liquid pH.

    Treatment: Electronic Cigarette

  • 1 of the other 2 remaining e-liquid pHOther group

    Using an electronic cigarette, the participant will complete a standardized vaping session using 1 of the other 2 assigned e-liquid pH.

    Treatment: Electronic Cigarette

  • Remaining e-liquid pHOther group

    Using an electronic cigarette, the participant will complete a standardized vaping session using the remaining assigned e-liquid pH.

    Treatment: Electronic Cigarette

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Record updated
15 July 2025